Earnings summaries and quarterly performance for Ovid Therapeutics.
Executive leadership at Ovid Therapeutics.
Board of directors at Ovid Therapeutics.
Research analysts who have asked questions during Ovid Therapeutics earnings calls.
ES
Eric Schmidt
Cantor Fitzgerald & Co.
1 question for OVID
Also covers: ADCT, AGIO, BIIB +9 more
JB
Jason Butler
JMP Citizens
1 question for OVID
Also covers: ACAD, AQST, ATHA +9 more
SW
Sarah Weber
Piper Jaffray Companies
1 question for OVID
TL
Tim Lugo
William Blair
1 question for OVID
Also covers: AKTX, BHVN, EYEN +3 more
YN
Yigal Nochomovitz
Citigroup Inc.
1 question for OVID
Also covers: ALDX, APLS, ARCT +22 more
Recent press releases and 8-K filings for OVID.
Ovid Therapeutics Stockholders Approve Share Increase and Securities Issuances
OVID
Proxy Vote Outcomes
Convertible Preferred Issuance
Executive Compensation
- Ovid Therapeutics Inc. held a special meeting of stockholders on December 11, 2025, with 53.42% of outstanding shares present or represented by proxy.
- Stockholders approved an amendment to increase the number of authorized shares of Common Stock from 125,000,000 to 315,000,000.
- Stockholders approved the issuance of Common Stock upon the conversion of Series B Preferred Stock and the exercise of Series A and Series B Warrants.
- Stockholders also approved the issuance and sale of Series B Preferred Stock, Series A Warrants, and Series B Warrants to Jeremy Levin, the Company's Chief Executive Officer.
Dec 11, 2025, 6:58 PM
Ovid Therapeutics Announces CEO Succession, Q3 2025 Financial Results, and Pipeline Updates
OVID
CEO Change
Earnings
New Projects/Investments
- Ovid Therapeutics Inc. announced a leadership succession plan, with Meg Alexander appointed Chief Executive Officer, effective January 1, 2026, succeeding Dr. Jeremy M. Levin, who will transition to Executive Chair of the Board.
- For the third quarter ended September 30, 2025, the company reported a net loss of $12.2 million, or $0.17 per share, compared to a net loss of $14.0 million, or $0.20 per share, for the same period in 2024. Revenue from royalty agreements was $132,000 for Q3 2025, down from $173,000 in Q3 2024.
- As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $25.6 million. A recent private placement, with an initial closing of approximately $81 million, is expected to extend the company's cash runway into 2H 2028.
- Key pipeline updates include positive Phase 1 results for OV329, supporting advancement to a Phase 2a study in Q2 2026, and first-in-human data for OV350 anticipated in Q4 2025. The first oral KCC2 direct activator, OV4071, is expected to enter the clinic in Q2 2026.
Nov 12, 2025, 12:02 PM
Ovid Therapeutics Announces Positive OV329 Trial Results and New Securities Issuance
OVID
Convertible Preferred Issuance
New Projects/Investments
- Ovid Therapeutics Inc. announced positive topline results from its Phase 1 healthy volunteer study for OV329, a next-generation GABA-aminotransferase inhibitor being developed for drug-resistant epilepsies, on October 3, 2025.
- The study demonstrated statistically significant inhibition of GABA-AT by OV329, matching or exceeding inhibition by vigabatrin, and showed a preferable safety and tolerability profile compared to marketed anti-seizure medicines.
- Ovid plans to advance OV329 into a Phase 2a study in drug-resistant focal onset seizures and is completing a final enabling study to support regulatory filings for its oral KCC2 direct activator, OV4071, in early 2026.
- On October 2, 2025, the company entered into a Securities Purchase Agreement to sell 57,722 shares of Series B Convertible Preferred Stock and warrants to purchase a total of 67,342,325 shares of common stock.
Oct 3, 2025, 9:09 PM
Ovid Therapeutics Reports Positive OV329 Phase 1 Data
OVID
New Projects/Investments
Guidance Update
- Ovid Therapeutics announced positive topline Phase 1 data for OV329, a next-generation GABA aminotransferase inhibitor targeting treatment-resistant epilepsies and focal onset seizures, demonstrating a favorable safety profile with clean ophthalmic results and inhibitory effects comparable to or exceeding Vigabatrin.
- The company plans to initiate a Phase 2A trial for OV329 in Q2 2026, with top-line proof-of-concept data expected by mid-2027.
- Ovid's pipeline also includes KCC2 direct activators, with OV350 Phase 1 data anticipated in Q4 2025 and the first oral KCC2 direct activator, OV4071, initiating Phase 1/1B studies in Q2 2026.
- Ovid Therapeutics has sufficient resources to fund its development programs through 2028.
Oct 3, 2025, 12:30 PM
Ovid Therapeutics Announces Positive Phase 1 OV329 Data and Pipeline Milestones
OVID
New Projects/Investments
Guidance Update
- Ovid Therapeutics successfully completed its Phase 1 safety and biomarker strategy for OV329, a next-generation GABA aminotransferase inhibitor, demonstrating a positive safety profile with clean ophthalmic results and target engagement.
- The company plans to initiate a Phase 2a trial for OV329 in Q2 2026, with top-line data anticipated in mid-2027 for treatment-resistant epilepsies and focal onset seizures.
- For its KCC2 program, top-line safety, tolerability, and PK data for the intravenous OV350 are expected in Q4 2025. The first oral KCC2 direct activator, OV4071, is slated for Phase 1/1b initiation in Q2 2026, with early proof of concept data in psychosis indications by Q1 2027.
- Ovid Therapeutics has sufficient resources to fund its development programs through 2028.
- The target market for OV329 in refractory and polypharmacy epilepsy and focal onset seizures represents approximately 40% of epilepsy patients and a >$1 billion commercial opportunity.
Oct 3, 2025, 12:30 PM
Ovid Therapeutics Announces Positive Topline Results for OV329 Phase 1 Study
OVID
New Projects/Investments
- Ovid Therapeutics announced positive topline results from its Phase 1 healthy volunteer study evaluating OV329, a next-generation GABA-aminotransferase inhibitor for drug-resistant epilepsies.
- The study confirmed statistically significant inhibition of GABA-AT, with OV329's inhibition matching or exceeding that demonstrated by therapeutic doses of vigabatrin.
- OV329 demonstrated a favorable safety and tolerability profile, notably showing no evidence of ophthalmic or retinal changes, which appears preferable relative to marketed anti-seizure medicines.
- Ovid plans to advance OV329 into a Phase 2a study in drug-resistant focal onset seizures, planned to initiate in Q2 2026.
- The company also provided pipeline updates, including anticipated regulatory filing for OV4071 (oral KCC2 direct activator) in Q1 2026 and topline data for OV350 (intravenous KCC2 direct activator) in Q4 2025.
Oct 3, 2025, 11:02 AM
Ovid Therapeutics Provides Pipeline and Financial Update at TD Cowen Conference
OVID
New Projects/Investments
Guidance Update
- Ovid Therapeutics reported a cash balance of $62.7 million at the end of Q3 2024, with capital expected to last into the second half of 2026.
- The company's lead clinical program, OV329, a GABA-aminotransferase inhibitor for drug-resistant epilepsies, is in Phase I with biomarker and safety data anticipated later in 2025.
- Ovid's KCC2 platform's lead program, OV350, a direct KCC2 activator with potential in psychoses, is set to begin human trials in Q1 2025, with initial data expected in early 2026.
Mar 3, 2025, 8:10 PM
Ovid Therapeutics Provides Pipeline and Financial Update
OVID
New Projects/Investments
Guidance Update
- Ovid Therapeutics reported a cash balance of $62.7 million at the end of Q3 2024, providing a cash runway into the second half of 2026.
- The company's lead clinical program, OV329, a next-generation GABA aminotransferase inhibitor for epilepsies, is in Phase I with human safety data showing no serious adverse events and mild, transient adverse events; a readout including biomarker data is expected later in 2025.
- The lead program from Ovid's KCC2 platform, OV350, a direct KCC2 activator, is anticipated to enter human trials in Q1 2025 and has demonstrated potential as an atypical antipsychotic in preclinical models, with initial data expected early 2026.
Mar 3, 2025, 8:10 PM
Ovid Therapeutics Provides Pipeline Update and Upcoming Milestones
OVID
New Projects/Investments
Guidance Update
- Ovid Therapeutics is advancing its pipeline, with OV-329, a next-generation GABA aminotransferase inhibitor, expecting Phase 1 data readouts later in 2025. This program aims to offer a safer and more potent alternative to Vigabatrin, which previously faced retinal toxicity issues.
- The company's novel KCC2 activator program is progressing rapidly, with the first direct KCC2 activator (OV-350, an IV formulation) entering human trials before the end of the current quarter (Q1 2025). An oral KCC2 program is anticipated to enter the clinic a year later, with potential proof of concept in 2026 for indications such as psychoses associated with Parkinson's disease and tinnitus.
- Ovid has paused its OV-888 program, a ROCK2 inhibitor for neurovascular indications, following recent negative data from external trials in the cerebral cavernous malformations field.
Feb 12, 2025, 9:00 PM
Ovid Therapeutics provides pipeline update at Oppenheimer conference
OVID
New Projects/Investments
Product Launch
Guidance Update
- Ovid Therapeutics is focused on developing medicines for neuronal hyperexcitability in neurology and neuropsychiatric conditions.
- The company's OV-329 program, a next-generation GABA aminotransferase inhibitor, is expected to have significant data readouts in 2025 from its Phase 1 program, including safety, tolerability, PK, and biomarkers for clinical effect and target engagement. This drug aims to be a safer and more potent alternative to Vigabatrin, which had peak US sales of $330 million for limited indications.
- Ovid is advancing its KCC2 direct activator platform, with the first program, OV-350 (an intravenous formulation), entering human trials in Q1 2025. An oral KCC2 program is expected to enter the clinic a year later, aiming for proof of concept in 2026 with the IV formulation.
- The OV-888 program, targeting cerebral cavernous malformations, has been paused due to recent negative clinical trial results from external studies, though the company retains regulatory clearance and IP to resume if warranted.
Feb 12, 2025, 9:00 PM
Quarterly earnings call transcripts for Ovid Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more